English

CONCERT PHARMACEUTICALS, INC.

EDGAR

CNCE Quarterly report (10-Q) · filed 2022-11-07

85 filing records in this dataset, filed from 2014-01-13 to 2022-11-07. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

8 thousand USD

2022 Q3 · USD

Exact inputs and evidence

Revenue: 8000 USD Source

Operating margin

-370,075%

2022 Q3 · %

Exact inputs and evidence

Operating Income: -29606000 USD Source
Revenue: 8000 USD Source

Operating cash flow

-26 million USD

2022 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -83185000 USD Source
Operating Cash Flow: -57227000 USD Source

Free cash flow

-26.1 million USD

2022 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -83185000 USD Source
Operating Cash Flow: -57227000 USD Source
Capital Expenditure: 265000 USD Source
Capital Expenditure: 169000 USD Source

Cash and cash equivalents: 95.2 million USD 2022-09-30 Source
Exact value

95189000 USD
Long-term debt including current maturities: 29.2 million USD 2017-06-30 Source
Exact value

29188000 USD
Shares outstanding: 47.9 million shares 2022-09-30 Source
Exact value

47934649 shares

Reported share-count change

47.92% · 15.5 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

32406815 shares · 2021-09-30· Source
47934649 shares · 2022-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

42 thousand USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Revenue: 32578000 USD · 2021-01-01 – 2021-12-31 Source
Revenue: 32565000 USD · 2021-01-01 – 2021-09-30 Source
Revenue: 0 USD · 2022-01-01 – 2022-03-31 Source
Revenue: 21000 USD · 2022-04-01 – 2022-06-30 Source
Revenue: 8000 USD · 2022-07-01 – 2022-09-30 Source

Net income

-126 million USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Net income: -80051000 USD · 2021-01-01 – 2021-12-31 Source
Net income: -43922000 USD · 2021-01-01 – 2021-09-30 Source
Net income: -37728000 USD · 2022-01-01 – 2022-03-31 Source
Net income: -23548000 USD · 2022-04-01 – 2022-06-30 Source
Net income: -28904000 USD · 2022-07-01 – 2022-09-30 Source

Operating cash flow

-110 million USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Operating cash flow: -55154000 USD · 2021-01-01 – 2021-12-31 Source
Operating cash flow: -28676000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: -32324000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -57227000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -32324000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -83185000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -57227000 USD · 2022-01-01 – 2022-06-30 Source

Capital expenditure

281 thousand USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Capital expenditure: 255000 USD · 2021-01-01 – 2021-12-31 Source
Capital expenditure: 239000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 92000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 169000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 92000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 265000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 169000 USD · 2022-01-01 – 2022-06-30 Source

Free cash flow

-110 million USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Operating cash flow: -55154000 USD · 2021-01-01 – 2021-12-31 Source
Operating cash flow: -28676000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: -32324000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -57227000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: -32324000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: -83185000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -57227000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 255000 USD · 2021-01-01 – 2021-12-31 Source
Capital expenditure: 239000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 92000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 169000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 92000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 265000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 169000 USD · 2022-01-01 – 2022-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2022-11-07.

Financial data available through: 2021-12-31.

Coverage by financial measure

Revenue: 10 of 11 periods available· newest 2021-12-31
Operating income: 10 of 11 periods available· newest 2021-12-31
Net income: 10 of 11 periods available· newest 2021-12-31
Operating cash flow: 10 of 11 periods available· newest 2021-12-31
Capital expenditure: 10 of 11 periods available· newest 2021-12-31
Total assets: 9 of 11 periods available· newest 2021-12-31
Total liabilities: 9 of 11 periods available· newest 2021-12-31
Current assets: 9 of 11 periods available· newest 2021-12-31
Current liabilities: 9 of 11 periods available· newest 2021-12-31
Cash and cash equivalents: 10 of 11 periods available· newest 2021-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2016-12-31
Shares outstanding: 9 of 11 periods available· newest 2021-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+312.3%

Prior period

USD 7.9 million

2020-01-01 – 2020-12-31
Current period

USD 32.58 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

32578000 − 7902000 = 24676000 USD

7902000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
32578000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · CONCERT PHARMACEUTICALS, INC. · 2021-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Year-over-year change in Revenue: 24676000 USD Concept: fundies:Revenue Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 32578000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/cnce-20211231.htm#944047 Filing: 000136792022000018 Input fundies:Revenue: 7902000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/cnce-20211231.htm#945104 Filing: 000136792022000018
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 5.29 million

Prior period

−USD 74.77 million

2020-01-01 – 2020-12-31
Current period

−USD 80.05 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-80051000 − -74766000 = -5285000 USD

-74766000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-80051000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · CONCERT PHARMACEUTICALS, INC. · 2021-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Year-over-year change in Net income: -5285000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -80051000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/cnce-20211231.htm#1586236 Filing: 000136792022000018 Input fundies:NetIncome: -74766000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/cnce-20211231.htm#1118216 Filing: 000136792022000018
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 13.88 million

Prior period

−USD 69.04 million

2020-01-01 – 2020-12-31
Current period

−USD 55.15 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-55154000 − -69037000 = 13883000 USD

-69037000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-55154000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · CONCERT PHARMACEUTICALS, INC. · 2021-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Year-over-year change in Operating cash flow: 13883000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -55154000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/cnce-20211231.htm#1160540 Filing: 000136792022000018 Input fundies:OperatingCashFlow: -69037000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/cnce-20211231.htm#1161593 Filing: 000136792022000018
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+21.4%

Prior period

USD 210,000

2020-01-01 – 2020-12-31
Current period

USD 255,000

2021-01-01 – 2021-12-31

Exact inputs and evidence

255000 − 210000 = 45000 USD

210000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
255000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · CONCERT PHARMACEUTICALS, INC. · 2021-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Year-over-year change in Capital expenditure: 45000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 255000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/cnce-20211231.htm#1163764 Filing: 000136792022000018 Input fundies:CapitalExpenditure: 210000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/cnce-20211231.htm#1164720 Filing: 000136792022000018
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2021 2021-01-01 – 2021-12-31

Revenue USD 32.58 million 100% of revenue
Operating costs Derived USD 110.09 million 338% of revenue
Operating income −USD 77.51 million −238% of revenue
Tax, interest and other Derived USD 2.54 million 7.8% of revenue
Net income −USD 80.05 million −246% of revenue

Cash

Operating cash flow −USD 55.15 million −169% of revenue
Capital expenditure USD 255,000 0.8% of revenue
Free cash flow Derived −USD 55.41 million −170% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2012 Operating loss: operating costs were 245% of revenue.
2013 Operating loss: operating costs were 117% of revenue.
2014 Operating loss: operating costs were 457% of revenue.
2015 36%63%
2016 Operating loss: operating costs were 29,506% of revenue.
2017 Net income was higher than operating income, so the split is not drawn.
2018 Operating loss: operating costs were 629% of revenue.
2019 Operating loss: operating costs were 7,437% of revenue.
2020 Operating loss: operating costs were 1,019% of revenue.
2021 Operating loss: operating costs were 338% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2012 2012-01-01 – 2012-12-31	12849000	31459000 Derived	-18610000	1834000 Derived	-20444000	-26895000 Derived	Source 2012-01-01 – 2012-12-31: 12849000 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: -18610000 USD Inspect Operating Income Open source 2012-01-01 – 2012-12-31: -20444000 USD Inspect Net Income Open source 2012-01-01 – 2012-12-31: -26427000 USD Inspect Operating Cash Flow Open source 2012-01-01 – 2012-12-31: 468000 USD Inspect Capital Expenditure Open source
2013 2013-01-01 – 2013-12-31	25408000	29818000 Derived	-4410000	1646000 Derived	-6056000	12655000 Derived	Source 2013-01-01 – 2013-12-31: 25408000 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -4410000 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -6056000 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: 13018000 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 363000 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	8576000	39174000 Derived	-30598000	1101000 Derived	-31699000	-30564000 Derived	Source 2014-01-01 – 2014-12-31: 8576000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -30598000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -31699000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -29760000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 804000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	66729000	41941000 Derived	24788000	614000 Derived	24174000	22193000 Derived	Source 2015-01-01 – 2015-12-31: 66729000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: 24788000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: 24174000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: 23061000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 868000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	174000	51341000 Derived	-51167000	-447000 Derived	-50720000	-46113000 Derived	Source 2016-01-01 – 2016-12-31: 174000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -51167000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -50720000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -45343000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 770000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	143891000	51242000 Derived	92649000	-2990000 Derived	95639000	103137000 Derived	Source 2017-01-01 – 2017-12-31: 143891000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: 92649000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: 95639000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: 104084000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 947000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	10505000	66089000 Derived	-55584000	440000 Derived	-56024000	-50898000 Derived	Source 2018-01-01 – 2018-12-31: 10505000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -55584000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -56024000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -48029000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 2869000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	1077000	80092000 Derived	-79015000	-849000 Derived	-78166000	-49446000 Derived	Source 2019-01-01 – 2019-12-31: 1077000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -79015000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -78166000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -48761000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 685000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	7902000	80549000 Derived	-72647000	2119000 Derived	-74766000	-69247000 Derived	Source 2020-01-01 – 2020-12-31: 7902000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -72647000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -74766000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -69037000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 210000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	32578000	110086000 Derived	-77508000	2543000 Derived	-80051000	-55409000 Derived	Source 2021-01-01 – 2021-12-31: 32578000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -77508000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -80051000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -55154000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 255000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 32.6M 2021

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Revenue	12849000	Revenue: 12849000 Open source
20132013-12-31	Revenue	25408000	Revenue: 25408000 Open source
20142014-12-31	Revenue	8576000	Revenue: 8576000 Open source
20152015-12-31	Revenue	66729000	Revenue: 66729000 Open source
20162016-12-31	Revenue	174000	Revenue: 174000 Open source
20172017-12-31	Revenue	143891000	Revenue: 143891000 Open source
20182018-12-31	Revenue	10505000	Revenue: 10505000 Open source
20192019-12-31	Revenue	1077000	Revenue: 1077000 Open source
20202020-12-31	Revenue	7902000	Revenue: 7902000 Open source
20212021-12-31	Revenue	32578000	Revenue: 32578000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

312.3% 2021

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Year over year	No prior comparable period	Revenue: 12849000 Open source
20132013-12-31	Year over year	97.7%	Revenue: 25408000 Open source Revenue: 12849000 Open source
20142014-12-31	Year over year	-66.2%	Revenue: 8576000 Open source Revenue: 25408000 Open source
20152015-12-31	Year over year	678.1%	Revenue: 66729000 Open source Revenue: 8576000 Open source
20162016-12-31	Year over year	-99.7%	Revenue: 174000 Open source Revenue: 66729000 Open source
20172017-12-31	Year over year	82,596%	Revenue: 143891000 Open source Revenue: 174000 Open source
20182018-12-31	Year over year	-92.7%	Revenue: 10505000 Open source Revenue: 143891000 Open source
20192019-12-31	Year over year	-89.7%	Revenue: 1077000 Open source Revenue: 10505000 Open source
20202020-12-31	Year over year	633.7%	Revenue: 7902000 Open source Revenue: 1077000 Open source
20212021-12-31	Year over year	312.3%	Revenue: 32578000 Open source Revenue: 7902000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -237.9% 2021

Net margin -245.7% 2021

Free cash flow margin -170.1% 2021

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Operating margin	-144.8%	Operating Income: -18610000 Open source Revenue: 12849000 Open source
20132013-12-31	Operating margin	-17.4%	Operating Income: -4410000 Open source Revenue: 25408000 Open source
20142014-12-31	Operating margin	-356.8%	Operating Income: -30598000 Open source Revenue: 8576000 Open source
20152015-12-31	Operating margin	37.1%	Operating Income: 24788000 Open source Revenue: 66729000 Open source
20162016-12-31	Operating margin	-29,406.3%	Operating Income: -51167000 Open source Revenue: 174000 Open source
20172017-12-31	Operating margin	64.4%	Operating Income: 92649000 Open source Revenue: 143891000 Open source
20182018-12-31	Operating margin	-529.1%	Operating Income: -55584000 Open source Revenue: 10505000 Open source
20192019-12-31	Operating margin	-7,336.6%	Operating Income: -79015000 Open source Revenue: 1077000 Open source
20202020-12-31	Operating margin	-919.3%	Operating Income: -72647000 Open source Revenue: 7902000 Open source
20212021-12-31	Operating margin	-237.9%	Operating Income: -77508000 Open source Revenue: 32578000 Open source
20122012-12-31	Net margin	-159.1%	Net Income: -20444000 Open source Revenue: 12849000 Open source
20132013-12-31	Net margin	-23.8%	Net Income: -6056000 Open source Revenue: 25408000 Open source
20142014-12-31	Net margin	-369.6%	Net Income: -31699000 Open source Revenue: 8576000 Open source
20152015-12-31	Net margin	36.2%	Net Income: 24174000 Open source Revenue: 66729000 Open source
20162016-12-31	Net margin	-29,149.4%	Net Income: -50720000 Open source Revenue: 174000 Open source
20172017-12-31	Net margin	66.5%	Net Income: 95639000 Open source Revenue: 143891000 Open source
20182018-12-31	Net margin	-533.3%	Net Income: -56024000 Open source Revenue: 10505000 Open source
20192019-12-31	Net margin	-7,257.8%	Net Income: -78166000 Open source Revenue: 1077000 Open source
20202020-12-31	Net margin	-946.2%	Net Income: -74766000 Open source Revenue: 7902000 Open source
20212021-12-31	Net margin	-245.7%	Net Income: -80051000 Open source Revenue: 32578000 Open source
20122012-12-31	Free cash flow margin	-209.3%	Revenue: 12849000 Open source Operating Cash Flow: -26427000 Open source Capital Expenditure: 468000 Open source
20132013-12-31	Free cash flow margin	49.8%	Revenue: 25408000 Open source Operating Cash Flow: 13018000 Open source Capital Expenditure: 363000 Open source
20142014-12-31	Free cash flow margin	-356.4%	Revenue: 8576000 Open source Operating Cash Flow: -29760000 Open source Capital Expenditure: 804000 Open source
20152015-12-31	Free cash flow margin	33.3%	Revenue: 66729000 Open source Operating Cash Flow: 23061000 Open source Capital Expenditure: 868000 Open source
20162016-12-31	Free cash flow margin	-26,501.7%	Revenue: 174000 Open source Operating Cash Flow: -45343000 Open source Capital Expenditure: 770000 Open source
20172017-12-31	Free cash flow margin	71.7%	Revenue: 143891000 Open source Operating Cash Flow: 104084000 Open source Capital Expenditure: 947000 Open source
20182018-12-31	Free cash flow margin	-484.5%	Revenue: 10505000 Open source Operating Cash Flow: -48029000 Open source Capital Expenditure: 2869000 Open source
20192019-12-31	Free cash flow margin	-4,591.1%	Revenue: 1077000 Open source Operating Cash Flow: -48761000 Open source Capital Expenditure: 685000 Open source
20202020-12-31	Free cash flow margin	-876.3%	Revenue: 7902000 Open source Operating Cash Flow: -69037000 Open source Capital Expenditure: 210000 Open source
20212021-12-31	Free cash flow margin	-170.1%	Revenue: 32578000 Open source Operating Cash Flow: -55154000 Open source Capital Expenditure: 255000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -55.2M 2021

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Operating cash flow	-26427000	Operating Cash Flow: -26427000 Open source
20132013-12-31	Operating cash flow	13018000	Operating Cash Flow: 13018000 Open source
20142014-12-31	Operating cash flow	-29760000	Operating Cash Flow: -29760000 Open source
20152015-12-31	Operating cash flow	23061000	Operating Cash Flow: 23061000 Open source
20162016-12-31	Operating cash flow	-45343000	Operating Cash Flow: -45343000 Open source
20172017-12-31	Operating cash flow	104084000	Operating Cash Flow: 104084000 Open source
20182018-12-31	Operating cash flow	-48029000	Operating Cash Flow: -48029000 Open source
20192019-12-31	Operating cash flow	-48761000	Operating Cash Flow: -48761000 Open source
20202020-12-31	Operating cash flow	-69037000	Operating Cash Flow: -69037000 Open source
20212021-12-31	Operating cash flow	-55154000	Operating Cash Flow: -55154000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -55.4M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Free cash flow	-26895000	Operating Cash Flow: -26427000 Open source Capital Expenditure: 468000 Open source
20132013-12-31	Free cash flow	12655000	Operating Cash Flow: 13018000 Open source Capital Expenditure: 363000 Open source
20142014-12-31	Free cash flow	-30564000	Operating Cash Flow: -29760000 Open source Capital Expenditure: 804000 Open source
20152015-12-31	Free cash flow	22193000	Operating Cash Flow: 23061000 Open source Capital Expenditure: 868000 Open source
20162016-12-31	Free cash flow	-46113000	Operating Cash Flow: -45343000 Open source Capital Expenditure: 770000 Open source
20172017-12-31	Free cash flow	103137000	Operating Cash Flow: 104084000 Open source Capital Expenditure: 947000 Open source
20182018-12-31	Free cash flow	-50898000	Operating Cash Flow: -48029000 Open source Capital Expenditure: 2869000 Open source
20192019-12-31	Free cash flow	-49446000	Operating Cash Flow: -48761000 Open source Capital Expenditure: 685000 Open source
20202020-12-31	Free cash flow	-69247000	Operating Cash Flow: -69037000 Open source Capital Expenditure: 210000 Open source
20212021-12-31	Free cash flow	-55409000	Operating Cash Flow: -55154000 Open source Capital Expenditure: 255000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

32.1% 2021

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2012-12-31	Liabilities / assets	Not reported	No source recorded
20132013-12-31	Liabilities / assets	99.6%	Total Liabilities: 39633000 Open source Total Assets: 39773000 Open source
20142014-12-31	Liabilities / assets	35.1%	Total Liabilities: 29629000 Open source Total Assets: 84454000 Open source
20152015-12-31	Liabilities / assets	11.1%	Total Liabilities: 16297000 Open source Total Assets: 146932000 Open source
20162016-12-31	Liabilities / assets	14.7%	Total Liabilities: 14801000 Open source Total Assets: 100395000 Open source
20172017-12-31	Liabilities / assets	7.2%	Total Liabilities: 15304000 Open source Total Assets: 211736000 Open source
20182018-12-31	Liabilities / assets	12.9%	Total Liabilities: 24807000 Open source Total Assets: 192547000 Open source
20192019-12-31	Liabilities / assets	26.2%	Total Liabilities: 36014000 Open source Total Assets: 137471000 Open source
20202020-12-31	Liabilities / assets	17.6%	Total Liabilities: 28101000 Open source Total Assets: 159263000 Open source
20212021-12-31	Liabilities / assets	32.1%	Total Liabilities: 53091000 Open source Total Assets: 165316000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

9.33× 2021

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2012-12-31	Current assets / current liabilities	Not reported	No source recorded
20132013-12-31	Current assets / current liabilities	2.14×	Current Assets: 34045000 Open source Current Liabilities: 15917000 Open source
20142014-12-31	Current assets / current liabilities	4.39×	Current Assets: 81720000 Open source Current Liabilities: 18618000 Open source
20152015-12-31	Current assets / current liabilities	21.75×	Current Assets: 144108000 Open source Current Liabilities: 6627000 Open source
20162016-12-31	Current assets / current liabilities	17.55×	Current Assets: 97729000 Open source Current Liabilities: 5570000 Open source
20172017-12-31	Current assets / current liabilities	31.92×	Current Assets: 205734000 Open source Current Liabilities: 6445000 Open source
20182018-12-31	Current assets / current liabilities	20.59×	Current Assets: 180149000 Open source Current Liabilities: 8749000 Open source
20192019-12-31	Current assets / current liabilities	6.77×	Current Assets: 116855000 Open source Current Liabilities: 17268000 Open source
20202020-12-31	Current assets / current liabilities	14.02×	Current Assets: 142724000 Open source Current Liabilities: 10178000 Open source
20212021-12-31	Current assets / current liabilities	9.33×	Current Assets: 150329000 Open source Current Liabilities: 16120000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2012 2012-01-01 – 2012-12-31	−USD 20.44 million Exact value Exact value: -20444000 USD 2012-01-01 – 2012-12-31: -20444000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CONCERT PHARMACEUTICALS, INC. · 2012-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Net Income: -20444000 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -20444000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000119312515073586/cnce-20141231.xml#884992 Filing: 000119312515073586 The citation records this snapshot. The page link may show a newer release later.	−USD 26.43 million Exact value Exact value: -26427000 USD 2012-01-01 – 2012-12-31: -26427000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CONCERT PHARMACEUTICALS, INC. · 2012-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Operating Cash Flow: -26427000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -26427000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000119312515073586/cnce-20141231.xml#877046 Filing: 000119312515073586 The citation records this snapshot. The page link may show a newer release later.	USD 468,000 Exact value Exact value: 468000 USD 2012-01-01 – 2012-12-31: 468000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CONCERT PHARMACEUTICALS, INC. · 2012-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Capital Expenditure: 468000 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 468000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000119312515073586/cnce-20141231.xml#884449 Filing: 000119312515073586 The citation records this snapshot. The page link may show a newer release later.	−USD 26.9 million Calculation and evidence -26427000 − 468000 USD Exact free cash flow: -26895000 USD 2012-01-01 – 2012-12-31: -26427000 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 468000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CONCERT PHARMACEUTICALS, INC. · 2012-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Free cash flow: -26895000 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -26427000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000119312515073586/cnce-20141231.xml#877046 Filing: 000119312515073586 Input fundies:CapitalExpenditure: 468000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000119312515073586/cnce-20141231.xml#884449 Filing: 000119312515073586 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	−USD 6.06 million Exact value Exact value: -6056000 USD 2013-01-01 – 2013-12-31: -6056000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CONCERT PHARMACEUTICALS, INC. · 2013-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Net Income: -6056000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -6056000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792016000014/cnce-20151231.xml#250885 Filing: 000136792016000014 The citation records this snapshot. The page link may show a newer release later.	USD 13.02 million Exact value Exact value: 13018000 USD 2013-01-01 – 2013-12-31: 13018000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CONCERT PHARMACEUTICALS, INC. · 2013-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Operating Cash Flow: 13018000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 13018000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792016000014/cnce-20151231.xml#250131 Filing: 000136792016000014 The citation records this snapshot. The page link may show a newer release later.	USD 363,000 Exact value Exact value: 363000 USD 2013-01-01 – 2013-12-31: 363000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CONCERT PHARMACEUTICALS, INC. · 2013-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Capital Expenditure: 363000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 363000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792016000014/cnce-20151231.xml#265757 Filing: 000136792016000014 The citation records this snapshot. The page link may show a newer release later.	USD 12.66 million Calculation and evidence 13018000 − 363000 USD Exact free cash flow: 12655000 USD 2013-01-01 – 2013-12-31: 13018000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 363000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CONCERT PHARMACEUTICALS, INC. · 2013-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Free cash flow: 12655000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 13018000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792016000014/cnce-20151231.xml#250131 Filing: 000136792016000014 Input fundies:CapitalExpenditure: 363000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792016000014/cnce-20151231.xml#265757 Filing: 000136792016000014 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 31.7 million Exact value Exact value: -31699000 USD 2014-01-01 – 2014-12-31: -31699000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CONCERT PHARMACEUTICALS, INC. · 2014-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Net Income: -31699000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -31699000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792017000009/cnce-20161231.xml#304328 Filing: 000136792017000009 The citation records this snapshot. The page link may show a newer release later.	−USD 29.76 million Exact value Exact value: -29760000 USD 2014-01-01 – 2014-12-31: -29760000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CONCERT PHARMACEUTICALS, INC. · 2014-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Operating Cash Flow: -29760000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -29760000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792017000009/cnce-20161231.xml#303573 Filing: 000136792017000009 The citation records this snapshot. The page link may show a newer release later.	USD 804,000 Exact value Exact value: 804000 USD 2014-01-01 – 2014-12-31: 804000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CONCERT PHARMACEUTICALS, INC. · 2014-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Capital Expenditure: 804000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 804000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792017000009/cnce-20161231.xml#319971 Filing: 000136792017000009 The citation records this snapshot. The page link may show a newer release later.	−USD 30.56 million Calculation and evidence -29760000 − 804000 USD Exact free cash flow: -30564000 USD 2014-01-01 – 2014-12-31: -29760000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 804000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CONCERT PHARMACEUTICALS, INC. · 2014-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Free cash flow: -30564000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -29760000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792017000009/cnce-20161231.xml#303573 Filing: 000136792017000009 Input fundies:CapitalExpenditure: 804000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792017000009/cnce-20161231.xml#319971 Filing: 000136792017000009 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	USD 24.17 million Exact value Exact value: 24174000 USD 2015-01-01 – 2015-12-31: 24174000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CONCERT PHARMACEUTICALS, INC. · 2015-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Net Income: 24174000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: 24174000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792018000012/cnce-20171231.xml#309651 Filing: 000136792018000012 The citation records this snapshot. The page link may show a newer release later.	USD 23.06 million Exact value Exact value: 23061000 USD 2015-01-01 – 2015-12-31: 23061000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CONCERT PHARMACEUTICALS, INC. · 2015-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Operating Cash Flow: 23061000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 23061000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792018000012/cnce-20171231.xml#308896 Filing: 000136792018000012 The citation records this snapshot. The page link may show a newer release later.	USD 868,000 Exact value Exact value: 868000 USD 2015-01-01 – 2015-12-31: 868000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CONCERT PHARMACEUTICALS, INC. · 2015-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Capital Expenditure: 868000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 868000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792018000012/cnce-20171231.xml#327607 Filing: 000136792018000012 The citation records this snapshot. The page link may show a newer release later.	USD 22.19 million Calculation and evidence 23061000 − 868000 USD Exact free cash flow: 22193000 USD 2015-01-01 – 2015-12-31: 23061000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 868000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CONCERT PHARMACEUTICALS, INC. · 2015-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Free cash flow: 22193000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 23061000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792018000012/cnce-20171231.xml#308896 Filing: 000136792018000012 Input fundies:CapitalExpenditure: 868000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792018000012/cnce-20171231.xml#327607 Filing: 000136792018000012 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 50.72 million Exact value Exact value: -50720000 USD 2016-01-01 – 2016-12-31: -50720000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CONCERT PHARMACEUTICALS, INC. · 2016-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Net Income: -50720000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -50720000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792019000009/cnce-20181231.xml#332343 Filing: 000136792019000009 The citation records this snapshot. The page link may show a newer release later.	−USD 45.34 million Exact value Exact value: -45343000 USD 2016-01-01 – 2016-12-31: -45343000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CONCERT PHARMACEUTICALS, INC. · 2016-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Operating Cash Flow: -45343000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -45343000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792019000009/cnce-20181231.xml#331707 Filing: 000136792019000009 The citation records this snapshot. The page link may show a newer release later.	USD 770,000 Exact value Exact value: 770000 USD 2016-01-01 – 2016-12-31: 770000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CONCERT PHARMACEUTICALS, INC. · 2016-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Capital Expenditure: 770000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 770000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792019000009/cnce-20181231.xml#350353 Filing: 000136792019000009 The citation records this snapshot. The page link may show a newer release later.	−USD 46.11 million Calculation and evidence -45343000 − 770000 USD Exact free cash flow: -46113000 USD 2016-01-01 – 2016-12-31: -45343000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 770000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CONCERT PHARMACEUTICALS, INC. · 2016-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Free cash flow: -46113000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -45343000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792019000009/cnce-20181231.xml#331707 Filing: 000136792019000009 Input fundies:CapitalExpenditure: 770000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792019000009/cnce-20181231.xml#350353 Filing: 000136792019000009 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	USD 95.64 million Exact value Exact value: 95639000 USD 2017-01-01 – 2017-12-31: 95639000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CONCERT PHARMACEUTICALS, INC. · 2017-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Net Income: 95639000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: 95639000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792019000009/cnce-20181231.xml#333335 Filing: 000136792019000009 The citation records this snapshot. The page link may show a newer release later.	USD 104.08 million Exact value Exact value: 104084000 USD 2017-01-01 – 2017-12-31: 104084000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CONCERT PHARMACEUTICALS, INC. · 2017-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Operating Cash Flow: 104084000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 104084000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792019000009/cnce-20181231.xml#331919 Filing: 000136792019000009 The citation records this snapshot. The page link may show a newer release later.	USD 947,000 Exact value Exact value: 947000 USD 2017-01-01 – 2017-12-31: 947000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CONCERT PHARMACEUTICALS, INC. · 2017-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Capital Expenditure: 947000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 947000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792019000009/cnce-20181231.xml#350562 Filing: 000136792019000009 The citation records this snapshot. The page link may show a newer release later.	USD 103.14 million Calculation and evidence 104084000 − 947000 USD Exact free cash flow: 103137000 USD 2017-01-01 – 2017-12-31: 104084000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 947000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CONCERT PHARMACEUTICALS, INC. · 2017-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Free cash flow: 103137000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 104084000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792019000009/cnce-20181231.xml#331919 Filing: 000136792019000009 Input fundies:CapitalExpenditure: 947000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792019000009/cnce-20181231.xml#350562 Filing: 000136792019000009 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 56.02 million Exact value Exact value: -56024000 USD 2018-01-01 – 2018-12-31: -56024000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CONCERT PHARMACEUTICALS, INC. · 2018-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Net Income: -56024000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -56024000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792020000013/cnce-20191231.xml#233901 Filing: 000136792020000013 The citation records this snapshot. The page link may show a newer release later.	−USD 48.03 million Exact value Exact value: -48029000 USD 2018-01-01 – 2018-12-31: -48029000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CONCERT PHARMACEUTICALS, INC. · 2018-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Operating Cash Flow: -48029000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -48029000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792020000013/cnce-20191231.xml#232862 Filing: 000136792020000013 The citation records this snapshot. The page link may show a newer release later.	USD 2.87 million Exact value Exact value: 2869000 USD 2018-01-01 – 2018-12-31: 2869000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CONCERT PHARMACEUTICALS, INC. · 2018-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Capital Expenditure: 2869000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2869000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792020000013/cnce-20191231.xml#250013 Filing: 000136792020000013 The citation records this snapshot. The page link may show a newer release later.	−USD 50.9 million Calculation and evidence -48029000 − 2869000 USD Exact free cash flow: -50898000 USD 2018-01-01 – 2018-12-31: -48029000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 2869000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CONCERT PHARMACEUTICALS, INC. · 2018-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Free cash flow: -50898000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -48029000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792020000013/cnce-20191231.xml#232862 Filing: 000136792020000013 Input fundies:CapitalExpenditure: 2869000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792020000013/cnce-20191231.xml#250013 Filing: 000136792020000013 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 78.17 million Exact value Exact value: -78166000 USD 2019-01-01 – 2019-12-31: -78166000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CONCERT PHARMACEUTICALS, INC. · 2019-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Net Income: -78166000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -78166000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792021000013/cnce-20201231.htm#1607133 Filing: 000136792021000013 The citation records this snapshot. The page link may show a newer release later.	−USD 48.76 million Exact value Exact value: -48761000 USD 2019-01-01 – 2019-12-31: -48761000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CONCERT PHARMACEUTICALS, INC. · 2019-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Operating Cash Flow: -48761000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -48761000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792021000013/cnce-20201231.htm#1154972 Filing: 000136792021000013 The citation records this snapshot. The page link may show a newer release later.	USD 685,000 Exact value Exact value: 685000 USD 2019-01-01 – 2019-12-31: 685000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CONCERT PHARMACEUTICALS, INC. · 2019-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Capital Expenditure: 685000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 685000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792021000013/cnce-20201231.htm#1158088 Filing: 000136792021000013 The citation records this snapshot. The page link may show a newer release later.	−USD 49.45 million Calculation and evidence -48761000 − 685000 USD Exact free cash flow: -49446000 USD 2019-01-01 – 2019-12-31: -48761000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 685000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CONCERT PHARMACEUTICALS, INC. · 2019-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Free cash flow: -49446000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -48761000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792021000013/cnce-20201231.htm#1154972 Filing: 000136792021000013 Input fundies:CapitalExpenditure: 685000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792021000013/cnce-20201231.htm#1158088 Filing: 000136792021000013 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 74.77 million Exact value Exact value: -74766000 USD 2020-01-01 – 2020-12-31: -74766000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CONCERT PHARMACEUTICALS, INC. · 2020-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Net Income: -74766000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -74766000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/cnce-20211231.htm#1118216 Filing: 000136792022000018 The citation records this snapshot. The page link may show a newer release later.	−USD 69.04 million Exact value Exact value: -69037000 USD 2020-01-01 – 2020-12-31: -69037000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CONCERT PHARMACEUTICALS, INC. · 2020-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Operating Cash Flow: -69037000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -69037000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/cnce-20211231.htm#1161593 Filing: 000136792022000018 The citation records this snapshot. The page link may show a newer release later.	USD 210,000 Exact value Exact value: 210000 USD 2020-01-01 – 2020-12-31: 210000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CONCERT PHARMACEUTICALS, INC. · 2020-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Capital Expenditure: 210000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 210000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/cnce-20211231.htm#1164720 Filing: 000136792022000018 The citation records this snapshot. The page link may show a newer release later.	−USD 69.25 million Calculation and evidence -69037000 − 210000 USD Exact free cash flow: -69247000 USD 2020-01-01 – 2020-12-31: -69037000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 210000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CONCERT PHARMACEUTICALS, INC. · 2020-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Free cash flow: -69247000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -69037000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/cnce-20211231.htm#1161593 Filing: 000136792022000018 Input fundies:CapitalExpenditure: 210000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/cnce-20211231.htm#1164720 Filing: 000136792022000018 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 80.05 million Exact value Exact value: -80051000 USD 2021-01-01 – 2021-12-31: -80051000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CONCERT PHARMACEUTICALS, INC. · 2021-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Net Income: -80051000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -80051000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/cnce-20211231.htm#1586236 Filing: 000136792022000018 The citation records this snapshot. The page link may show a newer release later.	−USD 55.15 million Exact value Exact value: -55154000 USD 2021-01-01 – 2021-12-31: -55154000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CONCERT PHARMACEUTICALS, INC. · 2021-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Operating Cash Flow: -55154000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -55154000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/cnce-20211231.htm#1160540 Filing: 000136792022000018 The citation records this snapshot. The page link may show a newer release later.	USD 255,000 Exact value Exact value: 255000 USD 2021-01-01 – 2021-12-31: 255000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CONCERT PHARMACEUTICALS, INC. · 2021-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Capital Expenditure: 255000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 255000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/cnce-20211231.htm#1163764 Filing: 000136792022000018 The citation records this snapshot. The page link may show a newer release later.	−USD 55.41 million Calculation and evidence -55154000 − 255000 USD Exact free cash flow: -55409000 USD 2021-01-01 – 2021-12-31: -55154000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 255000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CONCERT PHARMACEUTICALS, INC. · 2021-12-31 CONCERT PHARMACEUTICALS, INC. (edgar:1367920) Free cash flow: -55409000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:43:46Z Snapshot: 61324f700b80e9a92808da2832796761ca8cde5438fbcd1c7dbd3cf3d5fa7e28 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1367920?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -55154000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/cnce-20211231.htm#1160540 Filing: 000136792022000018 Input fundies:CapitalExpenditure: 255000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1367920/000136792022000018/cnce-20211231.htm#1163764 Filing: 000136792022000018 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

85 filings · 2,640 latest values · 2,640 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001367920, 1367920, CNCE, edgar:1367920

Also known as CONCERT PHARMACEUTICALS INC, CONCERT PHARMACEUTICALS, INC., Concert Pharmaceuticals, Inc.

CONCERT PHARMACEUTICALS, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2021 2021-01-01 – 2021-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation